Blueprint医药 BPMC 深 沪
交易中 08-15 09:49:38 美东时间
129.46
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 129.46
- 总市值 83.61亿
- 52周最高 129.65
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 73.04
- 委 比 0.00%
- 总股本 6458.22万
- 历史最高 129.65
- 量 比 0
- 振 幅 0.00%
- 历史最低 13.04
- 每 手 1
- 风险率 13.99%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy
Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.
07-23 02:09
What's Driving the Market Sentiment Around Blueprint Medicines?
Blueprint Medicines's (NYSE:BPMC) short percent of float has risen 17.61% since...
07-15 03:01
Cogent's Chronic Immune Disorder Drug Has Strong Potential To Become A Blockbuster: Analyst
Cogent's bezuclastinib showed strong efficacy in a non-advanced SM trial, with a planned FDA submission expected by the end of 2025.
07-09 02:26
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
06-18 09:46
Wells Fargo Downgrades Blueprint Medicines to Equal-Weight, Lowers Price Target to $129
Wells Fargo analyst Derek Archila downgrades Blueprint Medicines (NASDAQ:BPMC) from Overweight to Equal-Weight and lowers the price target from $143 to $129.
06-17 21:42
美股大行评级 | 潜在涨幅925.64%！Aemetis获Ascendiant Capital升目标价至20美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1138028221594226688.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持Aemetis(AMTX)"买入"评级，目标价从19美元升至20美元</p> <p>• Ascendiant Capital：维持Lucid Diagnostics(LUCD)"买
06-07 08:37
Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta
Byron Allen dials out, Salesforce logs in. Here are the various deal announcements of the past week plus bankruptcy updates.
06-07 03:37
美股大行评级 | 潜在涨幅6326.33%！Ascendiant Capital上调Plus Therapeutics目标价至20.5美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1137665801621229569.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持Plus Therapeutics(PSTV)"买入"评级，目标价从20美元升至20.5美元</p> <p>• Ascendiant Capital：维持RenovoRx(RNXT
06-06 09:45
UBS Maintains Neutral on Blueprint Medicines, Raises Price Target to $129
UBS analyst David Dai maintains Blueprint Medicines (NASDAQ:BPMC) with a Neutral and raises the price target from $88 to $129.
06-05 20:51
美股大行评级 | 花旗首予霸王茶姬"买入"评级，CrowdStrike、达乐公司、Guidewire Software、Snowflake获多家机构上调评级和目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1137304602125590529.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Wolfe Research：维持Cheche Group(CCG)"跑赢大市"评级，目标价从335美元升至350美元</p> <p>• HC Wainwright & Co.：上调AnaptysBio(ANAB)
06-05 09:42
